User: Guest  Login
Document type:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
Author(s):
Luber, B; Deplazes, J; Keller, G; Walch, A; Rauser, S; Eichmann, M; Langer, R; Höfler, H; Hegewisch-Becker, S; Folprecht, G; Wöll, E; Decker, T; Endlicher, E; Lorenzen, S; Fend, F; Peschel, C; Lordick, F 
Title:
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). 
Abstract:
The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, a...    »
 
Journal title abbreviation:
BMC Cancer 
Year:
2011 
Journal volume:
11 
Pages contribution:
509 
Language:
eng 
Fulltext / DOI:
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie